Cellectis (CLLS) Cash & Equivalents (2013 - 2026)

Cellectis' Cash & Equivalents history runs 14 years deep, the most recent figure standing at $34.8 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 72.7% year-over-year to $34.8 million; the TTM figure through Mar 2026 stood at $34.8 million (down 72.7% YoY), while the FY2025 annual figure was $61.5 million, down 57.05% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $34.8 million, down from $61.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $159.1 million in Q3 2024, with the low at $34.8 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $97.6 million (2022), against an average of $103.4 million.
• The sharpest annual moves came in 2024 and 2026: Cash & Equivalents surged 136.18% in 2024, then sank 72.7% in 2026.
• Cellectis' Cash & Equivalents stood at $93.2 million in 2022, then surged by 46.66% to $136.7 million in 2023, then rose by 4.79% to $143.3 million in 2024, then sank by 57.05% to $61.5 million in 2025, then tumbled by 43.38% to $34.8 million in 2026.
• Business Quant data shows CLLS's Cash & Equivalents at $34.8 million in Q1 2026, $61.5 million in Q4 2025, and $52.2 million in Q3 2025.